[go: up one dir, main page]

WO2008017752A3 - Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques - Google Patents

Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques Download PDF

Info

Publication number
WO2008017752A3
WO2008017752A3 PCT/FR2007/001309 FR2007001309W WO2008017752A3 WO 2008017752 A3 WO2008017752 A3 WO 2008017752A3 FR 2007001309 W FR2007001309 W FR 2007001309W WO 2008017752 A3 WO2008017752 A3 WO 2008017752A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
isobutyl
substituent
therapeutic uses
eucalyptus extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/001309
Other languages
English (en)
Other versions
WO2008017752A2 (fr
Inventor
Christel Fiorini-Puybaret
Bernard Fabre
Cecile Chauvin
Philippe Joulia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009000673A priority Critical patent/MX2009000673A/es
Priority to BRPI0714863-1A priority patent/BRPI0714863A2/pt
Priority to EP07823364A priority patent/EP2049133A2/fr
Priority to JP2009522297A priority patent/JP2010500974A/ja
Priority to US12/309,754 priority patent/US20090324754A1/en
Priority to CA002659162A priority patent/CA2659162A1/fr
Priority to AU2007283529A priority patent/AU2007283529A1/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to NZ574429A priority patent/NZ574429A/en
Publication of WO2008017752A2 publication Critical patent/WO2008017752A2/fr
Publication of WO2008017752A3 publication Critical patent/WO2008017752A3/fr
Priority to TN2009000018A priority patent/TN2009000018A1/fr
Priority to IL196788A priority patent/IL196788A0/en
Anticipated expiration legal-status Critical
Priority to NO20090951A priority patent/NO20090951L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)

Abstract

La présente invention concerne l'utilisation d'un extrait d'Eucalyptus pour la préparation d'un médicament ou d'un complément alimentaire destiné au traitement et/ou à la prévention des affections ou pathologies découlant d'un désordre de la recapture de neuromédiateurs. La présente invention concerne également un nouvel extrait enrichi d'Eucalyptus caractérisé en ce qu'il contient au moins 1 composé de formule (I) ou l'une quelconque de ses formes diastéréoisomères dans laquelle Rl forme avec le carbone auquel il est rattaché un groupement C=CH2, un groupement formule (II) et R2 re résente un rou ement isobut le,α-isobutyle ou β-isobutyle; ainsi que son procédé de préparation.
PCT/FR2007/001309 2006-08-01 2007-07-27 Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques Ceased WO2008017752A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002659162A CA2659162A1 (fr) 2006-08-01 2007-07-27 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
BRPI0714863-1A BRPI0714863A2 (pt) 2006-08-01 2007-07-27 extrato de eucalipto, processo de preparo e utilizaÇÕes terapÊuticas do mesmo
EP07823364A EP2049133A2 (fr) 2006-08-01 2007-07-27 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
JP2009522297A JP2010500974A (ja) 2006-08-01 2007-07-27 新規のユーカリ抽出物、その調製方法およびその治療利用法
US12/309,754 US20090324754A1 (en) 2006-08-01 2007-07-27 Eucalyptus extract, method of preparation and therapeutic uses thereof
AU2007283529A AU2007283529A1 (en) 2006-08-01 2007-07-27 Eucalyptus extract, method of preparation and therapeutic uses thereof
NZ574429A NZ574429A (en) 2006-08-01 2007-07-27 New eucalyptus extract, method of preparation and therapeutic uses thereof
MX2009000673A MX2009000673A (es) 2006-08-01 2007-07-27 Nuevo extracto de eucalipto, su procedimiento de preparacion y sus utilizaciones terapeuticas.
TN2009000018A TN2009000018A1 (fr) 2006-08-01 2009-01-19 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
IL196788A IL196788A0 (en) 2006-08-01 2009-01-29 New eucalyptus extract, method of preparation and therapeutic uses thereof
NO20090951A NO20090951L (no) 2006-08-01 2009-03-02 Nytt eukalyptusekstrakt, fremgangsmate for fremstilling og terapeutiske anvendelser derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607201A FR2904557B1 (fr) 2006-08-01 2006-08-01 Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
FR0607201 2006-08-01

Publications (2)

Publication Number Publication Date
WO2008017752A2 WO2008017752A2 (fr) 2008-02-14
WO2008017752A3 true WO2008017752A3 (fr) 2008-04-10

Family

ID=37708427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001309 Ceased WO2008017752A2 (fr) 2006-08-01 2007-07-27 Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques

Country Status (20)

Country Link
US (1) US20090324754A1 (fr)
EP (1) EP2049133A2 (fr)
JP (1) JP2010500974A (fr)
KR (1) KR20090034401A (fr)
CN (1) CN101511378A (fr)
AR (1) AR062165A1 (fr)
AU (1) AU2007283529A1 (fr)
BR (1) BRPI0714863A2 (fr)
CA (1) CA2659162A1 (fr)
FR (1) FR2904557B1 (fr)
IL (1) IL196788A0 (fr)
MA (1) MA30592B1 (fr)
MX (1) MX2009000673A (fr)
NO (1) NO20090951L (fr)
NZ (1) NZ574429A (fr)
RU (1) RU2445112C2 (fr)
TN (1) TN2009000018A1 (fr)
TW (1) TW200820961A (fr)
UA (1) UA99598C2 (fr)
WO (1) WO2008017752A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926547B1 (fr) * 2008-01-18 2010-04-23 Pf Medicament 5-°1-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h- cyclopropa°a!naphtalen-4-yl)-3-methylbutyl!-2,4,6-trihydroxy -1,3-benzenedicarboxaldehyde en tant que medicaments.
JP5602346B2 (ja) * 2008-06-17 2014-10-08 株式会社ロッテ ユーカリ抽出物の調製方法
GB2465228A (en) * 2008-11-15 2010-05-19 Athena Health Patents Inc Analogues of phloroglucinols from eucalyptus plant varieties and related compounds and their use in treating neurodegenerative disorders
CN102085169B (zh) * 2011-01-30 2012-08-29 广州中涵生物科技有限公司 一种使黑头溶解同步收细毛孔的制剂
PT106278B (pt) * 2012-04-26 2018-01-03 Raiz Inst De Investigação Da Floresta E Papel Método para a obtenção de um extrato rico em ácidos triterpénicos a partir da casca de eucalipto
KR102115037B1 (ko) * 2013-12-04 2020-05-25 코웨이 주식회사 상고머리 야테 추출물을 유효성분으로 함유하는 피부 미백용 화장료 조성물
US20160317596A1 (en) * 2013-12-18 2016-11-03 Thylabisco Ab Use of Thylakoids to Reduce the Urge for Palatable Food
CA3010636A1 (fr) 2016-06-29 2018-01-04 CannScience Innovations Inc. Resines de cannabis decarboxylees, leurs utilisations et leurs procedes de fabrication
CN109172554A (zh) * 2018-09-06 2019-01-11 淮安安莱生物科技有限公司 大果桉醛c在制备治疗人肝癌的药物方面的应用
KR102212193B1 (ko) 2019-07-15 2021-02-03 박경호 인동등 및 유칼립투스 추출물을 유효성분으로 포함하는 인지기능장애 예방 또는 치료용 조성물
JP7506371B2 (ja) * 2020-01-20 2024-06-26 国立大学法人浜松医科大学 ドーパミン減少抑制剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329297A1 (fr) * 1975-10-29 1977-05-27 Rougier Yves Inhalateur buccal
JPH08198765A (ja) * 1995-01-31 1996-08-06 Hayami Kinugawa 鎮痛用医薬組成物
US20030031735A1 (en) * 2000-01-18 2003-02-13 Nagaoka Perfumery Co., Ltd Anti-obestic composition
WO2003053336A2 (fr) * 2001-12-19 2003-07-03 The Quigley Corporation Procedes de traitement de malaises neurovasculaires peripheriques
JP2005272431A (ja) * 2004-03-24 2005-10-06 Yukio Kitagawa アロマセラピー品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3365782B2 (ja) * 1990-11-22 2003-01-14 株式会社ロッテ 新規マクロカルパール類及びその製造法
DE4447336C2 (de) * 1994-12-31 1996-12-19 Goebel Hartmut J Dr Med Habil Verwendung eines Gemisches aus Cineol und Menthol
JPH11137232A (ja) * 1997-08-02 1999-05-25 Ever Bright Ind Corp ハーブ製品
JP4809980B2 (ja) * 2000-01-18 2011-11-09 長岡香料株式会社 抗動脈硬化症剤
JP4979181B2 (ja) * 2003-01-31 2012-07-18 株式会社ヤクルト本社 グリケーション阻害剤及びその利用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329297A1 (fr) * 1975-10-29 1977-05-27 Rougier Yves Inhalateur buccal
JPH08198765A (ja) * 1995-01-31 1996-08-06 Hayami Kinugawa 鎮痛用医薬組成物
US20030031735A1 (en) * 2000-01-18 2003-02-13 Nagaoka Perfumery Co., Ltd Anti-obestic composition
WO2003053336A2 (fr) * 2001-12-19 2003-07-03 The Quigley Corporation Procedes de traitement de malaises neurovasculaires peripheriques
JP2005272431A (ja) * 2004-03-24 2005-10-06 Yukio Kitagawa アロマセラピー品

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AMAKURA Y ET AL: "Constituents and their antioxidative effects in eucalyptus leaf extract used as a natural food additive", FOOD CHEMISTRY 2002 UNITED KINGDOM, vol. 77, no. 1, 2002, pages 47 - 56, XP002467681, ISSN: 0308-8146 *
BILCHIK T R: "A review of nonvalidated and complementary therapies for cluster headache", CURRENT PAIN AND HEADACHE REPORTS 2004 UNITED KINGDOM, vol. 8, no. 2, 2004, pages 157 - 161, XP008075626, ISSN: 1531-3433 *
DATABASE WPI Week 199641, Derwent World Patents Index; AN 1996-408323, XP002422394 *
DATABASE WPI Week 200570, Derwent World Patents Index; AN 2005-680147, XP002422395 *
DI CARLO G ET AL: "St John's wort: Prozac from the plant kingdom", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 22, no. 6, 1 June 2001 (2001-06-01), pages 292 - 297, XP004241901, ISSN: 0165-6147 *
ESCHLER B M ET AL: "Distribution of foliar formylated phloroglucinol derivatives amongst Eucalyptus species", BIOCHEMICAL SYSTEMATICS AND ECOLOGY, vol. 28, no. 9, November 2000 (2000-11-01), pages 813 - 824, XP002422055, ISSN: 0305-1978 *
GHISALBERTI ET AL: "Bioactive Acylphfluoroglucinol derivatives from Eucalyptus species", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 41, no. 1, 1996, pages 7 - 22, XP002275146, ISSN: 0031-9422 *
MÜLLER W E ET AL: "Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract", PHARMACOPSYCHIATRY, GEORG THIEME VERLAG, STUTTGART, DE, vol. 31, no. SUPPL 1, June 1998 (1998-06-01), pages 16 - 21, XP002114724, ISSN: 0176-3679 *
NISHIZAWA M ET AL: "Macrocarpals: HIV-RTase inhibitors of Eucalyptus globulus", TETRAHEDRON LETTERS 1992 UNITED KINGDOM, vol. 33, no. 21, 1992, pages 2983 - 2986, XP002467682, ISSN: 0040-4039 *
PASS DAVID M ET AL: "Vertebrate herbivory on Eucalyptus-identification of specific feeding deterrents for common ringtail possums (Pseudocheirus peregrinus) by bioassay-guided fractionation of Eucalyptus ovata foliage", JOURNAL OF CHEMICAL ECOLOGY, vol. 24, no. 9, September 1998 (1998-09-01), pages 1513 - 1527, XP002422053, ISSN: 0098-0331 *
SILVA JEANE ET AL: "Analgesic and anti-inflammatory effects of essential oils of Eucalyptus.", JOURNAL OF ETHNOPHARMACOLOGY, vol. 89, no. 2-3, December 2003 (2003-12-01), pages 277 - 283, XP002422054, ISSN: 0378-8741 *
TANAKA T ET AL: "First stereoselective total synthesis of macrocarpal C: Structure elucidation of macrocarpal G", CHEMICAL COMMUNICATIONS 21 DEC 1997 UNITED KINGDOM, no. 24, 21 December 1997 (1997-12-21), pages 2401 - 2402, XP002467683, ISSN: 1359-7345 *
VEROTTA L: "ARE ACYLPHLOROGLUCINOLS LEAD STRUCTURES FOR THE TREATMENT OF DEGENERATIVE DISEASES?", PHYTOCHEMISTRY REVIEWS, KLUWER, NL, vol. 1, 2002, pages 389 - 407, XP008041092, ISSN: 1568-7767 *
W. FOLEY AND E. LASSAK: "The potential of bioactive constituents of Eucalyptus foliage as non-wood products from plantations", RURAL INDUSTRIES RESEARCH AND DEVELOPMENTAL CORPORATION, November 2004 (2004-11-01), Australia, pages 1 - 43, XP002422056, Retrieved from the Internet <URL:www.rirdc.gov.au/reports/AFT/04-154.pdf> *

Also Published As

Publication number Publication date
NO20090951L (no) 2009-04-24
TW200820961A (en) 2008-05-16
WO2008017752A2 (fr) 2008-02-14
RU2445112C2 (ru) 2012-03-20
MX2009000673A (es) 2009-02-04
KR20090034401A (ko) 2009-04-07
CN101511378A (zh) 2009-08-19
UA99598C2 (ru) 2012-09-10
FR2904557B1 (fr) 2010-04-30
FR2904557A1 (fr) 2008-02-08
JP2010500974A (ja) 2010-01-14
AR062165A1 (es) 2008-10-22
RU2009107166A (ru) 2010-09-10
TN2009000018A1 (fr) 2010-08-19
NZ574429A (en) 2012-01-12
BRPI0714863A2 (pt) 2013-05-21
EP2049133A2 (fr) 2009-04-22
US20090324754A1 (en) 2009-12-31
IL196788A0 (en) 2009-11-18
MA30592B1 (fr) 2009-07-01
CA2659162A1 (fr) 2008-02-14
AU2007283529A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
WO2008017752A3 (fr) Extrait d &#39; eucalyptus, son procede de preparation et ses utilisations therapeutiques
WO2006138518A8 (fr) Polytherapie destinee au traitement de troubles immuno-inflammatoires
WO2007136518A3 (fr) Traitement de troubles auto-immunitaires
WO2008033464A3 (fr) Dérivés d&#39;azétidinone et procédés d&#39;utilisation de ceux-ci
WO2005046575A3 (fr) Prodrogues a base d&#39;acides amines
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
WO2009064388A3 (fr) Inhibiteurs de la méthionine aminopeptidase humaine 1 et procédés de traitement de troubles
WO2006130399A3 (fr) Combinaisons et methodes therapeutiques comprenant des composes irm
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
PL2048948T3 (pl) Płynne kompozycje octanu wapnia
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l&#39;anxiete
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2008023063A3 (fr) Traitement de maladies du cartilage
WO2008011364A3 (fr) Compositions contenant de la quercétine
WO2007128802A3 (fr) Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY153408A (en) Novel methods
WO2004020403A3 (fr) Composition et procede accroissant et maintenant la production de neurotransmetteurs
ZA200707716B (en) Use of iron (III) complex compounds
WO2007016679A3 (fr) Formes posologiques combinees a base de levodopa et de carbidopa a liberation immediate et a liberation controlee
WO2008094054A3 (fr) Composés
WO2008076296A3 (fr) Méthode améliorant la fonction de ventilation
WO2008037937A3 (fr) Utilisation de composes de la famille des milbemycines pour le traitement de desordres dermatologiques chez l&#39;homme
WO2008005806A3 (fr) Procédés, compositions et composés thérapeutiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780033476.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823364

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000673

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007823364

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2659162

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 574429

Country of ref document: NZ

Ref document number: 602/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12309754

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007283529

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2009000061

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2009522297

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007283529

Country of ref document: AU

Date of ref document: 20070727

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097004185

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: A200901761

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2009107166

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714863

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090130